The pharmaceutical sector in India presents a intricate landscape, increasingly marked by concerns surrounding monopoly . While the nation boasts a vibrant generic market, a few major companies exert a disproportionate stake of the market , sparking questions about rivalry and consumer access to accessible treatments. This circumstance is fueled by

India's pharmaceutical landscape presents a complex picture, largely shaped by the considerable influence of a few leading players. While the sector is often lauded for its generic drug manufacturing capabilities, a closer examination reveals a degree of sector concentration that warrants scrutiny. These established companies, including entities li